Despite calls to increase awareness and education regarding hypertension in Africa, awareness of this condition remains dismally low, and current practices to treat hypertension in Africa are overwhelmingly ineffective, evidenced by very low control rates. Acculturation 1 and other pathophysiological reasons (salt sensitivity, suppressed renin-angiotensin system, autonomic imbalance with sympathetic overactivity) 2 have been advocated as potential causes of such a poor control. The African-PREDICT study was designed to address both requirements to track and monitor longitudinally the development of hypertension in healthy Black individuals, aged 20-30 years, while performing a comparison with White counterparts. Here some preliminary results are presented, showing that overall, the baseline Black and White cohort presented with similar ages, clinic and 24-h blood pressures, but Black adults had lower socioeconomic status and higher central systolic blood pressure than White individuals. This study gives an excellent opportunity to explore differences in genetic predisposition to hypertension between White and Black patients, and to test the hypothesis that some patients may have variants that predispose to both a Liddle phenotype and a primary aldosteronism phenotype.
Physical activity and exercise training
In peripheral artery disease Exercise training is highly recommended in peripheral artery disease (PAD), but similar to other pathological conditions, adherence is the Achilles' heel to the success of exercise training. 3, 4 In particular in PAD, it is poorly tolerated because of ischaemic leg pain. 5, 6 Near infrared spectroscopy permits the non-invasive detection of muscle ischaemia during exercise, allowing for characterization of tissue perfusion and oxygen utilization during training. In a study presented here, exercise training guided by these tools allowed to reach a similar beneficial effect on exercise tolerance with respect to the traditional pain-guided protocol in a small sample of individuals. However, the latter protocol induced a larger effect on mitochondrial oxidative function, as this may be proportional to the degree of tissue hypoxia during exercise.
In advanced chronic heart failure
The elderly heart failure population represents a frail group, an increasing challenge in clinical practice. 7 The beneficial effect combining exercise training with muscle electrical stimulation has been proposed to overcome barriers in improving exercise tolerance. 8 In a large senior advanced heart failure population, self reported physical activity level conducted before heart failure decompensation was inversely related to mortality. Also, after multivariate analysis, physical activity score predicted mortality independently of several demographic and clinical variables.
In congenital heart disease
In both heart failure and coronary artery disease, the combination of aerobic and strength exercise has been proposed as the optimal intervention to increase exercise capacity. 9, 10 Here it was hypothesized that improved strength capacity could be associated with better lung function and exercise capacity. This hypothesis was confirmed in 538 congenital heart disease patients, supporting the idea of the beneficial effect of strength training.
Lipid control treatment

High-density lipoprotein cholesterol as a target
In the past, epidemiological studies have supported an inverse relationship between high-density lipoprotein cholesterol (HDL-C) levels and the risk of cardiovascular disease. This led to focusing efforts not only on the development of lipid-lowering drugs but also on the development of drugs able to increase HDL-C levels. A large meta-analysis aimed to evaluate the impact of HDL-C-raising pharmacological interventions on the risk of cardiovascular outcomes. The authors analysed data from 31 randomized controlled clinical trials using fibrates, niacin and cholesteryl ester transfer protein inhibitors in more than 150,000 patients: cardiovascular mortality was not affected by treatment with these drugs. Interestingly, the analysis based on the use, or not, of statins as background therapy showed that cardiovascular mortality and myocardial infarction (MI) risk were significantly reduced in trials with no statin as background therapy (mainly fibrate trials), whereas adding a HDL-C-raising drug to a background statin therapy failed to show a clinical benefit.
Statin in primary prevention
Failure to achieve recommended lipid targets is not uncommon in clinical practice, often due to reduced compliance or adverse drug reaction.
11 Individuals (N ¼ 969,460) were initiated on a lipid-lowering drug for cardiovascular disease primary prevention and the occurrence of rhabdomyolysis was assessed. During 18,407,391 person-months exposed to statins, 168 events were observed, corresponding to an incidence of rhabdomyolysis of 1.10 per 10,000 personyears (1.54 in men vs. 0.81 in women). More potent statin (e.g. rosuvastatin 20 mg in men and women and simvastatin 40 mg in men) and the first months of treatment represented at-risk situations, which require appropriate monitoring, especially in men.
Secondary prevention in post-MI patients
Secondary prevention intervention in clinical practice is still far from being effectively implemented, 12, 13 with detrimental results on outcome.
14 In a randomized multicentre trial performed in Germany, a new intensive prevention programme after MI, coordinated by prevention assistants and using personal teachings and telemetric strategies for 12 months, was significantly superior to usual care in providing sustainable risk factor control and better quality of life.
Highlights from AHA Scientific Sessions 2018: prevention is back in the spotlight Two late-breaking clinical trials sessions were dedicated to the field of prevention, covering several fields, including inflammation reduction as a therapeutic means in atherosclerotic cardiovascular disease prevention, the presentation of the third sodium-dependent glucose transporter-2 inhibitor phase III outcome trial and, most importantly, the vast field of lipidology, from low-density lipoprotein-lowering agents, somewhat surprising results in the omega-3 field, to the new North American guideline on the management of blood cholesterol.
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